Jefferies published a report stating that from the perspective of market accounts, Yao Ming Biotech is currently at an inflection point, and it is believed that its risk and reward curves tend to rise more than downward. The bank gave it a “buy” rating, with a target price of HK$53.

Jefferies pointed out that investors are reaching consensus on the geopolitical issues faced by Pharmacovigilance. As the US Biological Act progresses, in particular, how to handle existing contracts will become more clear. Jeffrey explained that investors currently assume that the bill will be passed in some form; the bill should not be as severe as it seems, and they estimate that new projects from Yao Ming Biotech and even Chinese peers will come from the European Union, China, and other parts of the world rather than the US within the next 3 to 5 years.